Literature DB >> 29706301

Inflammatory breast cancer: The pathologists' perspective.

G Cserni1, E Charafe-Jauffret2, P J van Diest3.   

Abstract

Inflammatory breast cancer (IBC) is a clinico-pathological entity, which has specific features of inflammation and pathological evidence of cancer, most often involving dermal lymphatics. This review looks at IBC from the pathologists point of view. The diagnostic criteria and differential diagnosis are summarized first. The staging implications are described next. Despite the overall poor prognosis of IBC, it is heterogeneous in terms of most prognostic and predictive factors (such as histological type, grade, receptor status, intrinsic subtype, inflammatory infiltrate). It seems that some molecular features (genes expressed) are unique to IBC, and this may help to identify them as IBC at the molecular level. The key carcinogenetic pathways activated in IBC, the inflammatory pathways present in the disease as well as the relation of IBC to cancer stem cells are also briefly covered. Due to the relative rarity of IBC, preclinical trials are very important in the study of this entity, and models with stromal and microenvironmental elements are expected to outperform the traditional models without these features, as the microenvironment seems to be a key component of IBC.
Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Diagnosis; Inflammation; Inflammatory breast cancer; Microenvironment; Molecular background; Staging

Mesh:

Substances:

Year:  2018        PMID: 29706301     DOI: 10.1016/j.ejso.2018.04.001

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  7 in total

Review 1.  Magnetic resonance imaging in the evaluation of pathologic nipple discharge: indications and imaging findings.

Authors:  Naziya Samreen; Laura B Madsen; Celin Chacko; Samantha L Heller
Journal:  Br J Radiol       Date:  2021-02-05       Impact factor: 3.039

2.  Accumulation of amyloid beta (Aβ) and amyloid precursor protein (APP) in tumors formed by a mouse xenograft model of inflammatory breast cancer.

Authors:  Astrid Zayas-Santiago; Michelle M Martínez-Montemayor; Jadier Colón-Vázquez; Gabriela Ortiz-Soto; Jose G Cirino-Simonet; Mikhail Inyushin
Journal:  FEBS Open Bio       Date:  2021-10-26       Impact factor: 2.693

3.  High endogenous CCL2 expression promotes the aggressive phenotype of human inflammatory breast cancer.

Authors:  Ila Pant; Luca Grumolato; Anita Rogic; Ruben Fernandez-Rodriguez; Andrew Edwards; Suvendu Das; Aaron Sun; Shen Yao; Rui Qiao; Shabnam Jaffer; Ravi Sachidanandam; Guray Akturk; Rosa Karlic; Mihaela Skobe; Stuart A Aaronson
Journal:  Nat Commun       Date:  2021-11-25       Impact factor: 14.919

Review 4.  Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research.

Authors:  R Jagsi; G Mason; B A Overmoyer; W A Woodward; S Badve; R J Schneider; J E Lang; M Alpaugh; K P Williams; D Vaught; A Smith; K Smith; K D Miller
Journal:  Breast Cancer Res Treat       Date:  2022-01-01       Impact factor: 4.872

5.  Paracrine IL-6 Signaling Confers Proliferation between Heterogeneous Inflammatory Breast Cancer Sub-Clones.

Authors:  Riley J Morrow; Amr H Allam; Belinda Yeo; Siddhartha Deb; Carmel Murone; Elgene Lim; Cameron N Johnstone; Matthias Ernst
Journal:  Cancers (Basel)       Date:  2022-05-04       Impact factor: 6.639

Review 6.  Epigenetics in Inflammatory Breast Cancer: Biological Features and Therapeutic Perspectives.

Authors:  Flavia Lima Costa Faldoni; Cláudia Aparecida Rainho; Silvia Regina Rogatto
Journal:  Cells       Date:  2020-05-08       Impact factor: 6.600

7.  Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center.

Authors:  Tamer M Fouad; Naoto T Ueno; Robert K Yu; Joe E Ensor; Ricardo H Alvarez; Savitri Krishnamurthy; Anthony Lucci; James M Reuben; Wei Yang; Jie S Willey; Vicente Valero; Melissa L Bondy; Massimo Cristofinalli; Sanjay Shete; Wendy A Woodward; Randa El-Zein
Journal:  PLoS One       Date:  2018-09-24       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.